reports
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of...
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis of different hallmark lesions of HS shows that up to 25% of patients achieved inflammatory remission at Week 40, defined as a 100% reduction in abscesses (A1...
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneou...
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skinFollowing positive Phase 2 LILAC results, litifilimab is the only investigational program with consistent, positive efficacy results in multiple CLE studies; if approved l...
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial...
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositisBrepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global disease activity, muscle strength, skin disease, physical function, and corticosteroid reduc...
Decision of the US District Court for the Southern District of New Yor...
Decision of the US District Court for the Southern District of New York in the TriZetto re-trial Press Release Decision of the US District Court for the Southern District of New York in the TriZetto re-trial Paris, France – March 28, 2026 – Atos Group notes that on 27 March 2026 the United States District Court for the Southern District of New York issued its pre-judgment decision in the litigation between Syntel and Cognizant and its subsidiary TriZetto. The Court ordered Syntel to pay 236,9 million dollars (204,1 million euros1) to Cognizant/TriZetto. This amount is composed as follow...
Décision du tribunal américain du district Sud de New York dans le cad...
Décision du tribunal américain du district Sud de New York dans le cadre du nouveau procès TriZetto Communiqué de presse Décision du tribunal américain du district Sud de New York dans le cadre du nouveau procès TriZetto Paris, France – 28 mars 2026 – prend note que, le 27 mars 2026, le tribunal américain du district Sud de New York a rendu sa décision préalable au jugement final dans le litige opposant Syntel à Cognizant et sa filiale TriZetto. Le tribunal a condamné Syntel à verser 236,9 millions de dollars américains (204,1 millions d'euros 1) à Cognizant/TriZetto. Ce montant se déc...
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin ...
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, and clear or almost clear scalp psoriasis emerged by Week 4, highlighting envudeucitinib’s early onset and broad clinical benefitEnv...
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 stud...
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpointsData reinforce potential for Q12W dosing from the start Paris, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, ...
Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de ...
Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE, l’amlitelimab, administré 1x/4 sem. ou 1x/12 sem., a montré une augmentation progressive de l’efficacité, sans signe de plateau à la semaine 24 pour l’ensemble des critères d’évaluation.Les données confortent le potentiel d’une administr...
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis...
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeksCaregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infantsResults from additional studies acro...
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Rese...
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late-2027, respectively WATERTOWN, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader me...
Rocket Lab Successfully Launches 85th Mission and First Dedicated Laun...
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency MAHIA, New Zealand, March 28, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today successfully completed its first dedicated launch for the European Space Agency (ESA), demonstrating Electron’s key and growing role in supporting space agency missions with repeatable and reliable commercial launch services. The launch, named “Daughter Of The Stars”, lifted off from Rocket Lab Launch Comple...
Compagnie de l`Odet: 1 director
A director at Compagnie de l`Odet bought 679 shares at 1,231.000EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Dynamatic Technologies Limited: 1 director
A director at Dynamatic Technologies Limited sold 25,000 shares at 9,601.849INR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
GK Energy Ltd: 1 director
A director at GK Energy Ltd maiden bought 25,000 shares at 98.430INR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Buzz Capital Inc: 1 director
A director at Buzz Capital Inc bought 1,533,334 shares at 0.075CAD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Ottobock Se & Co. Kgaa: 1 director
A director at Ottobock Se & Co. Kgaa bought 1,000 shares at 54.250EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Arisinfra Solutions Ltd: 1 director
A director at Arisinfra Solutions Ltd sold 200,000 shares at 102.314INR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Es Sunlogy Berhad: 2 directors
Two Directors at Es Sunlogy Berhad sold/bought 46,900,000 shares at 0.200MYR. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Oasis Home Holding Berhad: 2 directors
Two Directors at Oasis Home Holding Berhad bought/sold 5,017,500 shares at between 0.319MYR and 0.320MYR. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
Cambridge Technology Enterprises Lt: 1 director
A director at Cambridge Technology Enterprises Lt sold 950,000 shares at 23.400INR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.